New thiopyrazolo[3,4-d]pyrimidine derivatives as anti-mycobacterial agents

被引：98

作者：

Ballell, Lluis ^{[1
]}

Field, Robert A.

Chung, Gavin A. C.

Young, Robert J.

机构：

[1] Univ E Anglia, Sch Chem Sci & Pharm, Ctr Carbohydrate Chem, Norwich NR4 7TJ, Norfolk, England

[2] GlaxoSmithKline, Med Res Ctr, Stevenage SG1 2NY, Herts, England

[3] GlaxoSmithKline, MMPD CEDD, DDW, Tres Cantos 28760, Spain

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 06期

基金：

英国生物技术与生命科学研究理事会;

关键词：

anti-mycobacterial; anti-tubercular; thiopyrazolopyrimidines; SAR; SULFOTRANSFERASE INHIBITORS; DISCOVERY; TUBERCULOSIS; DESIGN;

D O I：

10.1016/j.bmcl.2006.12.066

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The multiple parallel synthesis of a series of N,S-bis-alkylated thiopyrazolo[3,4-d]pyrimidines, based on sequential S- then N-alkylation, is reported. These compounds showed significant anti-mycobacterial activity (MICs down to < 2 mu/ml) and their potential as significant drug-like leads is substantiated through cytotoxicity evaluation and in silico profiling. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：1736 / 1740

页数：5

共 33 条

[11] Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium
Collins, LA
Franzblau, SG
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) : 1004 - 1009
[12] The growing burden of tuberculosis - Global trends and interactions with the HIV epidemic
Corbett, EL
Watt, CJ
Walker, N
Maher, D
Williams, BG
Raviglione, MC
Dye, C
[J]. ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (09) : 1009 - 1021
[13] Small-molecule inhibitors of the cell cycle
Crews, CM
Mohan, R
[J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2000, 4 (01) : 47 - 53
[14] Prospects for new antitubercular drugs
Duncan, K
Barry, CE
[J]. CURRENT OPINION IN MICROBIOLOGY, 2004, 7 (05) : 460 - 465
[15] ELION GB, 1993, J MED VIROL, P2
[16] Synthesis and antimycobacterial activity of 6-arylpurines:: The requirements for the N-9 substituent in active antimycobacterial purines
Gundersen, LL
Nissen-Meyer, J
Spilsberg, B
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (06) : 1383 - 1386
[17] Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor - Study of Lck- and FynT-dependent T cell activation
Hanke, JH
Gardner, JP
Dow, RL
Changelian, PS
Brissette, WH
Weringer, EJ
Pollok, K
Connelly, PA
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (02) : 695 - 701
[18] Combination of molecular modeling and quantitative structure-activity relationship analysis in the study of antimycobacterial activity of pyridine derivatives
Klimesová, V
Palát, K
Waisser, K
Klimes, J
[J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 207 (1-2) : 1 - 6
[19] New benzimidazole derivatives as antimycobacterial agents
Klimesová, V
Kocí, J
Waisser, K
Kaustová, J
[J]. FARMACO, 2002, 57 (04): : 259 - 265
[20] Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors
Knockaert, M
Gray, N
Damiens, E
Chang, YT
Grellier, P
Grant, K
Fergusson, D
Mottram, J
Soete, M
Dubremetz, JF
Le Roch, K
Doerig, C
Schultz, PG
Meijer, L
[J]. CHEMISTRY & BIOLOGY, 2000, 7 (06): : 411 - 422

← 1 2 3 4 →